Bolt Biotherapeutics (FRA:6LP0) Current Deferred Revenue: €0.55 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
53 GF Score
Price €5.18
GF Value €12.31
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Current Deferred Revenue?

Bolt Biotherapeutics FRA:6LP0 53 Current Deferred Revenue is €0.55 Mil as of Mar. 2026. GuruFocus rates FRA:6LP0 with a GF Score™ of 53/100 and a GF Value™ of €12.31. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Bolt Biotherapeutics's current deferred revenue for the quarter that ended in Mar. 2026 was €0.55 Mil.

Bolt Biotherapeutics Current Deferred Revenue Related Terms

Bolt Biotherapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Current Deferred Revenue Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 2.54 1.88 2.02 2.88 0.38

Bolt Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.18 1.63 0.38 0.55
FRA:6LP0
53GF Score
Bolt Biotherapeutics Inc FRA:6LP0
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.55 Mil mean?
Bolt Biotherapeutics (FRA:6LP0) has a Current Deferred Revenue of €0.55 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bolt Biotherapeutics and its competitors.
Is Bolt Biotherapeutics' Current Deferred Revenue too high?
Bolt Biotherapeutics' current Current Deferred Revenue is €0.55 Mil. Overall, Bolt Biotherapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Current Deferred Revenue compare to AIM and ERNA?
Bolt Biotherapeutics' Current Deferred Revenue of €0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current Current Deferred Revenue is €0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current Current Deferred Revenue of €0.55 Mil. The stock's GF Value™ is €12.31, compared to a current price of €5.18 — trading 57.9% below its estimated fair value. The current Current Deferred Revenue is €0.55 Mil. Bolt Biotherapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current Current Deferred Revenue is €0.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 57.9% below its estimated GF Value™ of €12.31.

Key valuation signals for FRA:6LP0:

  • Current Deferred Revenue: €0.55 Mil
  • GF Value™: €12.31 vs. price of €5.18 (57.9% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score

Get the complete analysis for FRA:6LP0

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€12.31
GF Value